Dry age related macular degeneration

This study tests an experimental drug called AVD-104, given as an eye injection, for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The trial involves 300 participants and aims to see if the drug is safe and can slow …

This early feasibility trial tests a new retinal implant called PRIMA in 5 people with advanced dry age-related macular degeneration who have lost central vision. The device is surgically placed in the eye to stimulate remaining retinal cells. Researchers are checking if it is sa…

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…

This study tests the safety of a single injection of PST-611, a DNA-based therapy, in people aged 50 and older with dry age-related macular degeneration (AMD). The therapy is designed to make the eye produce a protein that may protect against vision loss. Participants receive one…

This study investigates whether a non-invasive light treatment called photobiomodulation can improve vision and slow vision loss in people with dry age-related macular degeneration (AMD). Participants receive either active light therapy or a sham (inactive) treatment over 12 mont…

This study checks the long-term safety of an eye injection called avacincaptad pegol for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 278 adults who finished a previous study of this drug will receive the injec…

This study tested a tiny implant called the PRIMA Bionic Vision System in 5 people with advanced dry age-related macular degeneration who had lost central vision. The implant is placed under the retina and uses electrical stimulation to replace damaged light-sensing cells. The go…

This study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The treatment is injected into the eye and aims to slow the growth of damaged areas. Researchers measured chan…

This study tested whether injecting a concentrated form of a patient's own blood, called platelet-rich plasma (PRP), into the eye could slow the progression of advanced dry age-related macular degeneration (AMD). Fourteen people with advanced dry AMD received three PRP injections…

This study tested whether the antibiotic minocycline, taken as a pill twice daily for at least 3 years, could safely slow the growth of geographic atrophy—an advanced form of age-related macular degeneration that causes blind spots. Thirty-seven adults aged 55 and older with geog…

This study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a place…

This study tested an eye injection called Zimura (avacincaptad pegol) in 448 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes permanent vision loss. The goal was to see if the drug could slow the growth of damaged areas in the retin…

This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a…

This study followed 20 adults aged 55 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes central vision loss. Researchers measured how the damaged area in the eye changed over nearly 4 years using eye exams and photos. The goal was…

This study tests whether a special camera called the OcuMet Beacon can detect stressed cells in the retina of people with geographic atrophy, an advanced form of age-related macular degeneration. Researchers want to see if the patterns of stress match areas of damage seen on stan…

This study compared two different eye imaging machines (Clarus and Optos) to see how well they measure geographic atrophy, a form of vision loss from age-related macular degeneration. Researchers enrolled 62 patients and took images with each device, then compared the measurement…

This study examined how vision loss progresses in people with geographic atrophy, an advanced form of dry age-related macular degeneration. Researchers analyzed past medical records and eye images from 60 patients to see which retinal changes are linked to faster vision decline. …

This completed study collected eye images from 1,000 people with intermediate age-related macular degeneration (AMD) to create a detailed database. Researchers will analyze these images to find signs that predict whether the disease will worsen to advanced stages. The goal is to …

This study tested a new type of camera that can see individual cells in the retina, which standard clinical cameras cannot do. Five people with retinal disease (inherited degeneration or toxicity) had their eyes scanned with the device. The goal was to compare image quality and o…

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related…